ICAM-3 Regulates Lymphocyte Morphology and Integrin-mediated T Cell Interaction with Endothelial Cell and Extracellular Matrix Ligands

Miguel R. Campanero, Paloma Sánchez-Mateos, Miguel A. del Pozo, and Francisco Sánchez-Madrid
Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain

Abstract. Leukocyte activation is a complex process that involves multiple cross-regulated cell adhesion events. In this report, we investigated the role of intercellular adhesion molecule-3 (ICAM-3), the third identified ligand for the β2 integrin leukocyte function-associated antigen-1 (LFA-1), in the regulation of leukocyte adhesion to ICAM-1, vascular cell adhesion molecule-1 (VCAM-1), and the 38- and 80-kD fragments of fibronectin (FN40 and FN80). The activating anti-ICAM-3 HP2/19, but not other anti-ICAM-3 mAb, was able to enhance T lymphoblast adhesion to these proteins when combined with very low doses of anti-CD3 mAb, which were unable by themselves to induce this phenomenon. In contrast, anti-ICAM-1 mAb did not enhance T cell attachment to these substrata. T cell adhesion to ICAM-1, VCAM-1, FN40, and FN80 was specifically blocked by anti-LFA-1, anti-VLAβ4, and anti-VLAα5 mAb, respectively. The activating anti-ICAM-3 HP2/19 was also able to specifically enhance the VLA-4- and VLA-5-mediated binding of leukemic T Jurkat cells to VCAM-1, FN40, and FN80, even in the absence of cooccupancy of the CD3-TcR complex. We also studied the localization of ICAM-3, LFA-1, and the VLAβ1 integrin, by immunofluorescence microscopy, on cells interacting with ICAM-1, VCAM-1 and FN80. We found that the anti-ICAM-3 HP2/19 mAb specifically promoted a dramatic change on the morphology of T lymphoblasts when these cells were allowed to interact with those adhesion ligands. Under these conditions, it was observed that a large cell contact area from which an uropod-like structure (heading uropod) was projected toward the outer milieu. However, when T blasts were stimulated with other adhesion promoting agents as the activating anti-VLAβ1 TS2/16 mAb or phorbol esters, this structure was not detected. The anti-ICAM-3 TP1/24 mAb was also unable to induce this phenomenon. Notably, a striking cell redistribution of ICAM-3 was induced specifically by the HP2/19 mAb, but not by the other anti-ICAM-3 mAb or the other adhesion promoting agents. Thus, ICAM-3 was almost exclusively concentrated in the most distal portion of the heading uropod whereas either LFA-1 or the VLAβ1 integrin were uniformly distributed all over the large contact area. Moreover, this phenomenon was also observed when T cells were specifically stimulated with the HP2/19 mAb to interact with TNFα-activated endothelial cells. We found the localization of linear arrays of myosin within the heading uropod. In contrast, actin-based cytoskeleton presented a uniform distribution over the broad contact area with the substrate. In addition, butanedione monoxime, a myosin-disrupting drug, abolished both the morphological cell change and ICAM-3 clustering. Altogether, these results demonstrate that ICAM-3 has a regulatory role on multiple pathways of T cell adhesion and morphology.
T and B lymphocytes and monocytes interact through the very late activation antigen (VLA)-4 (α4β1) and VLA-5 (α5β1) integrins with several distinct sequences of human plasma fibronectin. Thus, VLA-5 recognizes the Arg-Gly-Asp sequence, while VLA-4 recognizes the CSI, CS5, and HI peptides of fibronectin (FN) (Wayner et al., 1989; García-Pardo et al., 1990; Mould and Humphries, 1991; Mould et al., 1991). Several proteolytic fragments can be obtained by trypsin digestion of FN. Among them, the 38-kD (FN40) and 80-kD (FN80) fragments are recognized by the VLA-4 and VLA-5 integrins, respectively (Wayner et al., 1989; García-Pardo et al., 1990; Yamada, 1991). In addition, VLA-4 interacts with a cell surface ligand termed vascular cell adhesion molecule (VCAM)-1 (Elices et al., 1990), which belongs to the Immunoglobulin gene superfamily and has been shown to be expressed by cytokine-stimulated endothelial cells (Osborn et al., 1989). VLA-4 and VLA-5 interaction with fibronectin as well as VLA-4/VCAM-1 interaction appear to be essential for several physiologic processes such as B lymphocyte maturation (Roldán et al., 1992), lymphopoiesis (Williams et al., 1991), myogenesis (Rosen et al., 1992), leukocyte extravasation to the sites of inflammation (Laffèn et al., 1991; Postigo et al., 1992; Yednock et al., 1992), and T lymphocyte activation (Matsuyama et al., 1993; Hernández-Caselles et al., 1993). We have recently shown that ICAM-3 participates in T cell activation and regulates the LFA-1/ICAM-1 adhesion pathway in these cells (Campanero et al., 1993; Hernández-Caselles et al., 1993). We have herein studied the functional role of ICAM-3 on T cell adhesion. We have found that this molecule is also involved in the regulation of T cell binding to ICAM-1, VCAM-1, and fibronectin, as well as in the control of cellular morphology. The relevance of these findings is discussed.

**Materials and Methods**

**Antibodies, Protein Substrata, and Reagents**

The anti-ICAM-3 HP2/19 and TPI/24, anti-CD1a TSI/11 and TPI/40, anti-ICAM-1 RR1 and R5, and anti-CD29 T2/16, anti-CD49d HP2/1, anti-CD49e SAM-1, and anti-CD3 SPVT3b mAb have been described (Sánchez-Madrid et al., 1983, 1986; Hemler et al., 1984; Spits et al., 1985; Rothlein et al., 1986; Smith et al., 1988; Te Velde et al., 1988; Campanero et al., 1993). SAM-1 and RR1 and R5 and R5D6 mAbs were a generous gift of Dr. C. Figdor (Netherlands Cancer Institute, Amsterdam, The Netherlands) and R. Rothlein (Boehringer Ingelheim, Ridgefield, CT), respectively. MAB were purified from ascites fluid with protein A coupled to Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden), affinity-purified anti-β-actin rabbit sera were a generous gift of Dr. K. Burnidge (University of North Carolina, Chapel Hill, NC). Anti-mysobin rabbit polyclonal serum was purchased from Sigma Chem. Co. (St. Louis, MO). Recombinant chimeric ICAM-1–Fc and recombinant soluble (rs) VCAM-1 and endothelial leukocyte adhesion molecule-1 (rsELAM-1) were kindly provided by Dr. A. Craig (John Radcliffe Hospital, Oxford, Great Britain) and R. Lobb (Biogen, Cambridge, MA), respectively. The tryptic 38- and 80-kD fibronectin fragments were kindly provided by Dr. A. García-Pardo (Centro de Investigaciones Biológicas, Madrid, Spain). FITC-conjugated phalloidin, cytochalasin D, colchicine, and butanedione monoxime were purchased from Sigma Chem. Co.

**Cells and Cell Lines**

Human T lymphoblasts were prepared from peripheral blood mononuclear cells by treatment with phytomegagglutinin (PHA, 0.5%); Pharmacia Fine Chemicals) for 48 h. Cells were washed and cultured in RPMI 1640 (Flow Lab, Irvine, Scotland) containing 10% FCS (Flow Lab.) and 20 U/ml IL-2. T lymphoblasts cultured by 7–12 d were typically used in all experiments. T lymphoblasts and T cell clones were extensively used to study both LFA-1-mediated cell adhesion and T cell activation (Cantrell et al., 1984; van Kooyk et al., 1991; Dransfield et al., 1992; Campanero et al., 1993). The Jurkat T cell line was maintained in RPMI 1640 plus 10% FCS.

Human umbilical vein endothelial cells (HUVEC) were obtained as described (Dejana et al., 1987). Briefly, umbilical vein was cannulated, washed, and incubated with 0.1% collagenase P (Boehringer Mannheim GmbH, Mannheim, Germany) for 20 min at 37°C. Cells were seeded into flasks and cultured in M199 medium (Flow Lab.) supplemented with 20% FCS, 50 μg/ml endothelial cell growth supplement, and 100 μg/ml heparin (Sigma Chem. Co.). Cells within two passages were used. Cells were split 1:3 and detached with a solution of 0.05% Trypsin and 0.02% EDTA (Flow Lab.) before using.

**Cell Adhesion Assays**

Adhesion assays were essentially performed as previously described (Arroyo et al., 1992). Briefly, 50 μl/well of 20 mM Tris–HCl, pH 8.0, containing FN fragments, recombinant chimeric ICAM-1–Fc, rsVCAM-1, or rsELAM-1, were used to coat 96-well microtiter EIA II-Linbro plates (Costar, Cambridge, MA) for 2 h at 37°C and then saturated with PBS containing 1% HSA for 30 min at 37°C. Thereafter, plates were washed with PBS and either 2–3 × 10^5 (T lymphoblasts) or 1 × 10^6 (Jurkat cells) cells/well in 100 μl were added and centrifuged for 5 min at 10 g before an incubation at 37°C for 10–20 min. To quantify cell attachment, the plate was washed with RPMI containing 0.5% HSA, cells were fixed with a mixture of acetone/methanol 1:1 and dyed with violet crystal 0.5%. Then, absorbance at 540 nm was measured in an ELISA reader (LR400; Kallestad, Chaska, MN) and optical density was found to be a linear function of number of cells by a calibration curve (optical density vs. number of cells). Total cellular input was calculated by spinning wells with original number of cell aliquots, staining, and measuring optical density.

**Immunofluorescence**

Immunofluorescence experiments were performed as previously described (Sánchez-Mateos et al., 1993). Briefly, 2 × 10^5 T lymphoblasts were incubated in flat-bottomed, 24-well plates (Costar Corp., Cambridge, MA) in a final volume of 500 μl of complete medium on coverslips coated with 40 μg/ml ICAM-1–Fc, 20 μg/ml FN80, or 10 μg/ml VCAM-1–FN-80. For some experiments, HUVEC were grown on gelatin-coated coverslips and stimulated with 10 ng/ml TNFα for 16 h at 37°C; then, T lymphoblasts were incubated on these coverslips. MAB or their F(ab') fragments were added at a final concentration of 1 μg/ml and cells were allowed to settle in a cell incubator at 37°C and 5% CO2 atmosphere; after 30 min cells were fixed with 3.7% formaldehyde in PBS for 10 min at room temperature and rinsed in TBS (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% NaN3). To directly visualize the stimulatory mAB, cells were stained with a 1:50 dilution of an FITC-labeled rabbit F(ab')2 anti-mouse IgG (Pierce, Rockford, IL) as a secondary antibody. For double label studies, after directly staining the stimulatory mAB, cells were saturated with 10% nonspecific mouse serum in TBS. Then, cells were incubated with 5 μg/ml biotinylated mAB to other proteins, followed by washing and
Regulation of β1 and β2 Integrin-mediated Cellular Interactions through ICAM-3

We have recently shown that LFA-1/ICAM-1 interaction can be regulated through ICAM-3 (Campanero et al., 1993). We have now tested the possibility that ICAM-3 could also regulate the T cell binding to other endothelial cell adhesion molecules as VCAM-1 and ELAM-1. As shown in Fig. 1, the anti-ICAM-3 HP2/19 mAb was able to enhance T lymphoblast attachment to both ICAM-1 and VCAM-1, but not to ELAM-1; this effect was observed only when the anti-ICAM-3 mAb was combined with very low doses of anti-CD3 mAb, which were unable by themselves to induce this effect. When we used an anti-ICAM-3 mAb of identical Ig subclass and comparable affinity but directed against another different epitope (TPI/24), or anti-ICAM-1 mAbs, no effect was detected (Fig. 1). ICAM-3-mediated increased cell binding to ICAM-1 and VCAM-1 was specifically inhibited by mAbs to the LFA-1 and VLA-4 integrins, respectively (Fig. 2). Therefore, these results show that ICAM-3 is capable to regulate the interaction of LFA-1 and VLA-4 with their respective endothelial cell counter-receptors.

Since it has been described that VLA-4 interacts with the 38-kD fibronectin fragment containing CS-1 (Wayner et al., 1989), we tested the possibility that ICAM-3 could also regulate this interaction. As shown in Fig. 3, the anti-ICAM-3 HP2/19 mAb enhanced the VLA-4-mediated T lymphoblast adhesion to this fragment. Moreover, we have obtained evidence suggesting that ICAM-3 is also capable to regulate the VLA-5-mediated cell adhesion to its ligand. Thus, the HP2/19 mAb was able to enhance T lymphoblast adhesion to the 80-kD FN fragment containing the Arg-Gly-Asp peptide, and this event was specifically blocked by the anti-VLAa5 SAM-1 mAb (Fig. 3). However, the anti-ICAM-3 TPI/24, as well as the anti-ICAM-1 RR1/1 and R6.5D6 mAb failed to enhance cell adhesion to both FN fragments (Fig. 3). In addition, cell binding to fibrinogen was not enhanced by the anti-ICAM-3 HP2/19 mAb (data not shown).

When the Jurkat T cell line was stimulated with the anti-ICAM-3 HP2/19 mAb in the absence of anti-CD3 mAb, a dramatic increase in cell adhesion to either VCAM-1, FN40, or FN80, but not to ELAM-1 or fibrinogen, was observed (Fig. 4, and data not shown). Moreover, these effects...
Figure 3. Induction of T cell adhesion to fibronectin fragments by ICAM-3. T lymphoblasts were pretreated for 30 min at 4°C with a combination of different doses of the anti-CD3 T3b mAb with either RPMI (●), HP2/19 (●), TP1/24 (▲), RRI/1 (○), or R6.5D6 (□) mAbs (A and C). Next, 10 µg/ml sheep anti-mouse IgG was added, as cross-linker, for 10 min at 4°C. Cells activated with the anti-ICAM-3 antibody HP2/19 were subjected to integrin blockade (B and D). To this end, after cell treatment with the cross-linker agent, cells were incubated for additional 15 min at 4°C with either RPMI (●), HP2/1 (○), or SAM-1 (▲) mAbs. In B and D cell treatment with no additional stimulus to anti-CD3 mAb is also shown (●). Adhesion to microtiter wells coated with either 5 µg/ml FN40 (A and B) or FN80 (C and D) was quantified after 10 min of incubation at 37°C. Arithmetic mean ±SD of four separate experiments run by duplicate are shown. Adhesion to albumin- or fibrinogen-coated wells was always lower than 5%.

were specifically blocked by either anti-VLAα4 HP2/1 (VCAM-1 and FN40) or the anti-VLAα5 SAM-1 (FN80) mAb (Fig. 4). These results strongly suggest that ICAM-3 is able to transduce stimulatory signals in T cells even in the absence of CD3-TcR occupancy.

ICAM-3 Redistribution During T Cell Attachment to Different Adhesion Ligands

We have performed double immunofluorescence analysis to investigate the distribution of ICAM-3 when cells were in-
Figure 4. ICAM-3-mediated induction of Jurkat cell adhesion to VCAM-1 and fibronectin fragments in the absence of CD3-TcR stimulation. Jurkat cells were pretreated for 30 min at 4°C with different mAbs. Adhesion to microtiter wells coated with 5 µg/ml of either rsVCAM-1, FN40, or FN80 was quantified after 7 min of incubation at 37°C. Arithmetic mean ±SD of five separate experiments run by duplicate are shown. Adhesion to albumin- or fibrinogen-coated wells was always lower than 5%.

HP2/19 mAb were settled on BSA instead of ICAM-1 (data not shown).

Double exposure for ICAM-3 and LFA-1 fluorescence on the same cells was taken in the same photographs in order to compare the distribution of LFA-1 and ICAM-3 on cells interacting with ICAM-1. Fig. 5 C clearly shows that LFA-1 (red fluorescence) and ICAM-3 (green fluorescence) localized to different areas on the same cells upon T lymphoblast stimulation with the anti-ICAM-3 HP2/19 mAb: LFA-1 uniformly distributed all over the large flattened contact area whereas ICAM-3 selectively decorated the heading uropod. In contrast, on unstimulated cells, LFA-1 and ICAM-3 displayed a completely overlapping pattern of staining (orange color) (Fig. 5 L). Next, the distribution of ICAM-3 and the β1 integrin was analyzed when T blasts were allowed to settle on either VCAM-1 or FN80. The appearance of the heading uropod and ICAM-3 redistribution to this projection was observed in HP2/19 mAb-treated cells (Fig. 5, D and G), but not on unstimulated T blasts (data not shown). In contrast, the β1 integrin was uniformly distributed over the large contact area with either the VCAM-1- or the FN80-coated surfaces on both treated and mAb untreated T blasts (Fig. 5, E and H, and data not shown). Double exposure for ICAM-3 and β1 integrin fluorescence on the same cells clearly demonstrated that both molecules localized to different areas when these cells were interacting with VCAM-1 or FN80 (Fig. 5, F and I).

Other stimuli, as phorbol esters or the regulatory anti-VLAβ1 TS2/16 mAb, have previously been described to enhance integrin-mediated cell adhesion to ICAM-1, VCAM-1, and FN (Dustin and Springer, 1989; Arroyo et al., 1992). However, the appearance of the heading uropod was specifically induced by the anti-ICAM-3 HP2/19. When T blasts were stimulated to interact with FN80 with the anti-VLAβ1 TS2/16 mAb or PMA, the heading uropod and the ICAM-3 redistribution were not observed (Fig. 6, C and D). Moreover, ICAM-3-mediated change of morphology is epitope-specific since the other anti-ICAM-3 TP1/24 mAb, which is directed against a different epitope, failed to enhance T cell adhesion, and it had no effect on these events (Fig. 6 B). Moreover, the latter mAb also failed to induce cell clustering of ICAM-3 (Fig. 6 B). Virtually all ICAM-3 molecules appeared to be sequestered in the uropod, as demonstrated with cells treated with the activating HP2/19 mAb, and then stained with the TP1/24 mAb (data not shown).

ICAM-3 Redistribution During T Cell Interaction with Endothelial Cells

To explore the possible in vivo relevance of ICAM-3-mediated induction of the heading uropod, we tested the ability of ICAM-3 to stimulate the appearance of this structure when T cells interact with endothelial cells. Human umbilical vein endothelial cells stimulated for 16 h with TNFα express both ICAM-1 and VCAM-1. When T lymphoblasts were stimulated to interact with these endothelial cells with the anti-ICAM-3 HP2/19 mAb, the heading uropod and the ICAM-3 redistribution were clearly observed (Fig. 7 A). In contrast, the anti-ICAM-3 TP1/24 mAb was unable to induce the appearance of the heading uropod or ICAM-3 clustering (Fig. 7 B). Moreover, phorbol esters also failed to induce both phenomena (Fig. 7 C).
Figure 5. Cellular localization of ICAM-3 and LFA-1 during T lymphoblast attachment to ICAM-1, VCAM-1, and FN80. T lymphoblasts were allowed to bind to coverslips coated with either 40 μg/ml ICAM-1-Fc (A-C and J-L), 10 μg/ml rsVCAM-1 (D-F), or 20 μg/ml FN80 (G-I) for 30 min at 37°C either in the presence (A-I) or absence (J-L) of the anti-ICAM-3 HP2/19 mAb. Then, fixed cells were double stained for ICAM-3 (A, D, G, and J) and LFA-1 (B and K) or VLA81 (E and H) as described in Materials and Methods. In C, F, I, and L, red and green fluorescence was photographed on the same frame by double exposure. The heading uropod and the cell contact area with the substratum were indeed in a distinct plane of focus. Bar, 10 μm.

Cytoskeletal Reorganization during ICAM-3 Regulated T Cell Morphological Changes

To investigate the nature of the cytoplasmic interactions that drive ICAM-3 into the uropod region, the localization of f-actin and various cytoskeletal proteins was observed by fluorescence microscopy on ICAM-3-induced T cells adhering to FN80 (Fig. 8). F-actin was present through the cytoplasm of the cells, but brighter fluorescence was detected in the area of contact with the substrate (Fig. 8 A). Three other cytoskeletal proteins, talin, α-actinin (Fig. 8, B and C), and vinculin (not shown) demonstrated no preferential distribution to the cell uropod, where ICAM-3 was specifically concentrated (Fig. 8, E, F, and G), and similarly to f-actin, they displayed more pronounced fluorescence at the trailing membrane.
Actin polymerization contributes to the protrusion of cell margins such as lamellipodia, but recent reports have described forms of cell protrusion that may instead be driven by myosin (Conrad et al., 1993; Cramer et al., 1994). Fig. 8D shows the asymmetric distribution of myosin during cell adhesion to FN80 induced with the activating anti-ICAM-3 HP2/19 mAb. Cell uropods contained linear arrays of myosin, while a punctate distribution was observed uniformly through the rest of the cytoplasm.

To further investigate the involvement of the myosin motor in the generation of the cell uropod and ICAM-3 reorganization, we used the myosin-disrupting drug butanedione monoxime (Cramer et al., 1994). All cells treated with butanedione monoxime acquired a spherical morphology with a uniform distribution of ICAM-3 (Fig. 9B). However, cell attachment to FN80 was not affected by this treatment (Fig. 9B, and data not shown). In contrast, disruption of microtubules with colchicine did not affect the polarization of ICAM-3 (Fig. 9C). As expected, treatment of the cells with a microfilament disrupting element, cytochalasin D, resulted in a complete inhibition of cell adhesion (not shown).

Discussion

In this study, we have shown that ICAM-3 is a regulatory molecule that modulates β1 and β2 integrin-mediated T cell binding to endothelial cell surface molecules, as ICAM-1 and VCAM-1, and to ECM components as fibronectin. In addition, ICAM-3 distribution on the cell surface and T lymphoblast morphology were dramatically modified upon cell stimulation through ICAM-3.

It has been considered that integrins have an active functional role in cell activation, whereas their ligands do not. Thus, integrin ligands apparently only support cell attachment, whereas integrins display a more dynamic role. As a consequence of the interaction with their ligands, integrins transduce signals to the inside of cells, leading to changes in the cellular behavior. For instance, costimulatory signals are generated in T cells after LFA-1- and VLA-4-mediated...
interactions with ICAM-1 and VCAM-1 (Burkly et al., 1991; van Seventer et al., 1991; Hernández-Caselles et al., 1993). In contrast, no evidence exists regarding ICAM-1- and VCAM-1-mediated stimulation of endothelial cells upon this interaction. Interestingly, we have herewith demonstrated that ICAM-3, the third identified counter-receptor for the leucocyte integrin LFA-1, is also a regulatory molecule able to modulate both cell binding to different proteins and cell morphology. These results suggest that other integrin counter-receptors could also have an active functional role. In this regard, the absence of a regulatory role for ICAM-1 in our system might be due to the particular ICAM-1 mAbs employed.

Stimuli that activate T lymphocytes, such as phorbol esters or antibodies against the CD3-TeR complex or the CD2 antigen, also activate the integrins expressed on the cell surface (Springer, 1990). In addition, the β1, β2, and β3 integrins can be activated upon binding of regulatory mAbs to these integrins (Gulino et al., 1990; van Kooyk et al., 1991; Arroyo et al., 1992; Robinson et al., 1992). The mechanism responsible for the regulation of integrins by ICAM-3 likely involves cell activation since this phenomenon has been observed upon cell treatment with the stimulatory anti-ICAM-3 HP2/19 mAb (Campanero et al., 1993; Hernández-Caselles et al., 1993). In addition, since regulation through ICAM-3 of LFA-1, VLA-4, and VLA-5 activity seems to be due to T cell activation, we can expect that additional integrins on these cells are also regulated through this LFA-1 counter-receptor.

Activation of T lymphocytes with a wide number of stimuli involves the rise of intracellular calcium levels and/or PKC activation. It has recently been reported that mAb directed to certain epitopes of ICAM-3, when crosslinked with second anti-Ig antibodies, induce a rise in intracellular calcium concentrations (Juan et al., 1994). However, when we analyzed the possibility that mAb engagement of ICAM-3 could induce these intracellular events, no increase of intracellular calcium levels was observed upon anti-ICAM-3 cell treatment (our unpublished observations). Our previous results showing that the expression of the AIM/CD69 activation an-
Figure 8. Double immunofluorescence staining of ICAM-3 and cytoskeletal proteins on T lymphoblasts. Cells were induced to adhere on FN80 for 30 min at 37°C by using the activating anti-ICAM-3 HP2/19 mAb. After fixation, ICAM-3 was detected directly with rhodamine-conjugated goat F(ab')2 anti-mouse Ig (E-H). Cytoskeletal proteins in the same cells were detected after permeabilization with FITC-conjugated phalloidin to stain filamentous actin (A), and with rabbit antisera against α-actinin (B), talin (C), and myosin (D) followed by FITC-conjugated donkey F(ab')2 anti-rabbit Ig. Bar, 10 μm.

tigen on T lymphocytes could be induced upon cell treatment with the anti-ICAM-3 HP2/19 mAb (Hernández-Caselles et al., 1993) strongly suggest that PKC activation could be involved in ICAM-3-mediated cellular responses. AIM/CD69 is an inducible cell surface molecule whose expression on T lymphocytes is dependent on the activation of PKC (Cebrián et al., 1989). However, no conclusive results could be obtained on the putative involvement of this intracellular signaling pathway during ICAM-3-mediated regulation of cell binding to fibronectin by using PKC inhibitors as Staur opioid and H7 (our unpublished observations). Interestingly enough, recent evidence demonstrate the induction of tyrosine phosphorylation of different protein substrates in T cells by antibody engagement of ICAM-3 molecule (Arroyo et al., 1994; Juan et al., 1994). Moreover, the CD45 leukocyte tyrosine phosphatase appears to be involved in the regulation of ICAM-3-mediated signaling and cell-cell interactions (Arroyo et al., 1994).

We have reported that phorbol esters as well as the activating anti-ICAM-3 HP2/19 and anti-VLA-β1 TS2/16 mAb, regulate leukocyte binding to endothelial cells and ECM components (Arroyo et al., 1992; and this report). Interest
Figure 9. Effect of the myosin-disrupting drug butanedione monoxime on cell distribution of ICAM-3. Cells were induced to adhere on FN80 with the activating anti–ICAM-3 HP2/19 mAb, in the absence (A) or in the presence of 10 mM butanedione monoxime (B), and 10 μM colchicine (C). Cells were fixed and ICAM-3 was directly visualized by rhodamine-conjugated F(ab')2 anti-mouse Ig. Bar, 10 μm.

ingly, these stimuli differ in their ability to promote changes on the cellular morphology. ICAM-3 seems to be unique for stimulating the generation of the heading uropod. Both phorbol esters and the anti–VLA-β1 TS2/16 mAb also induced cell spreading on ICAM-1 and VCAM-1 (Arroyo et al., 1992; Sánchez-Mataceos et al., 1993), but the heading uropod was not detected. The recruitment of ICAM-3 to the uropod was observed on both T blast and Jurkat cells by engagement of ICAM-3 with the activating antibody without further cross-linking, as well as by coengagement of ICAM-3 and CD3-TcR (unpublished observations). Hence, both the raising of the heading uropod and ICAM-3 redistribution might be early events in the cellular activation cascade since both phenomena are observed under activating as well as under nonactivating conditions. In addition, clustering of ICAM-3 and uropod generation are epitope-specific since an anti–ICAM-3 mAb of identical Ig isotype and comparable affinity, but directed against a different epitope, was not able to induce any of either events. Interestingly, this phenomenon also took place when T cells were stimulated through ICAM-3 to interact with endothelial cells instead of purified proteins. In this regard, it has been reported that lymphocyte interactions with endothelial cells induced pseudopod formation; the adhesion molecules CD2, CD44, and L-selectin, but not LFA-1, were redistributed to this structure (Rosenman et al., 1993).

The heading uropod may have a functional role and might be essential for the recruitment of other leukocytes to inflammatory foci because: (a) it is very well exposed since it is projected towards the outer milieu outgoing from the flattened cellular area in contact with the substratum; (b) ICAM-3 is highly concentrated there, thus facilitating LFA-1-mediated interaction of other leukocytes; and (c) we have previously shown that on small cell aggregates, T lymphocytes come in contact through a uropod where ICAM-3 is accumulated (Campanero et al., 1993). In good agreement, it has been postulated that a good exposure of the L-Selectin on neutrophils facilitates its interaction with its counter-receptor on endothelial cells (Picker et al., 1991). In addition, the local clustering of the leukocyte integrin Mac-1 or its ligand iC3b has been shown to facilitate their mutual interaction (Detmers et al., 1987; Hermanowski-Vosatka et al., 1988).

Another LFA-1 counter-receptor, ICAM-1, has previously been reported to be redistributed on the cell surface of JY cells to an uropod-like structure that apparently interacts with LFA-1-coated surfaces (Dustin et al., 1992). Therefore, relocation of ICAMs to adhesive cellular areas seems to be a common characteristic of ICAMs. This similarity suggests that ICAM-1 and ICAM-3 might share common features on their cytoplasmic tails that would enable them to interact with the same set of cytoskeletal proteins. However, this does not appear to be the case because we have previously shown that ICAM-3 and ICAM-1 localized to different cell areas on cell aggregates induced through ICAM-3 (Campanero et al., 1993).

In the same regard, it has been previously reported that the cytoplasmic tail of ICAM-1 interacts with the actin-containing cytoskeleton and α-actinin (Carpen et al., 1992). In contrast, ICAM-3 colocalizes neither with major actin concentrations in the cell nor with three other cytoskeletal focal adhesion proteins, talin, α-actinin, and vinculin. Actin-based cytoskeleton appeared to be more concentrated in the broad area of contact with the substrate most distant from the cell uropod. Interestingly enough, the presence of linear arrays of myosin within the uropod region supports a role for myosin motor in both driving ICAM-3 towards the uropod and in the generation of this cellular structure. Accordingly, a myosin-disrupting drug completely abolished both events. These findings are in good agreement with previous reports suggesting that myosin mediates membrane motility in Dictostelium, Swiss 3T3 fibroblasts and the dorsal lip in Drosophila (Cramer et al., 1994; Fath and Burgess, 1994).

There is "cross-talk" between leukocyte and integrin activation, since each process is involved in the regulation of the other. Thus, leukocyte activation leads to integrin molecules...
activation enabling them to interact with their ligands and, on the other hand, ligand binding by integrins contributes to leukocyte activation. Our results suggest that ICAM-3 has an essential role in this cross-talk. In this regard, we have previously shown that T cell activation enhances LFA-1-mediated T cell binding to ICAM-3 (Campanero et al., 1993). Herewith, we have shown that engagement of ICAM-3 with mAb enhances the integrin-mediated binding to components of endothelial cells (ICAM-1 and VCAM-1) and extracellular matrix (fibronectin). In addition, it has been reported that activation of T lymphocytes through the CD3–T-cell receptor complex is markedly enhanced by integrin-mediated adhesion events (Matsuyama et al., 1989; Burlky et al., 1991; van Seventer et al., 1991; Hernández-Caselles et al., 1993), as well as by ICAM-3 itself (Hernández-Caselles et al., 1993).

We propose a model for the participation of ICAM-3 in leukocyte migration to inflammatory foci. LFA-1–activated bearing cells (e.g., antigen-presenting cells) could bind to resting T lymphocytes through LFA-1–ICAM-3 interactions that could induce mutual capping of both molecules that, in turn, would reinforce cell stimulation on both cells (Campanero et al., 1993; Hernández-Caselles et al., 1993). This interaction might be mimicked by the ICAM-3–HP2/19 mAb in our in vitro system. Next, activated leukocytes would bind to endothelial cells through LFA-1–ICAM-1 and VLA-4/VCAM-1 interactions. Leukocytes would spread out on the endothelium and the heaping uropod, where ICAM-3 would be concentrated, would raise from the flattened area of the cell, in close contact with the endothelial cell, towards the lumen of the vessel. The enormous density of ICAM-3 on this structure together with its location in the lumen of the vessel, would facilitate the interaction with the LFA-1 on circulating leukocytes which would be recruited and possibly stimulated.

We thank Dr. R. Lob (rsVCAM-1 and r6ELAM-1), A. Craig (ICAM-1–Fc), R. Rothlein (RR1/1 and R6.5D6 mAbs), and C. Figdor (SAM-1 mAb) for kindly providing chimaeric recombinant proteins and mAbs; Dr. A. García-Pardo for her generous gift of 38- and 80-kD Fn fragments; and Dr. R. González-Amaro for critical reading of the manuscript.

This work was supported by grants from P892-03/18 and CAM 028/92 to F. Sánchez-Madrid and by fellowships from Spanish Ministerio Educación y Ciencia (to M. R. Campanero), and INSALUD (to M. A. Del Pozo). Received for publication 21 February 1994 and in revised form 17 June 1994.
Matsuyama, T., A. Yamada, J. Kay, K. M. Yamada, S. K. Akiyama, S. F. Marlin, S. D., and T. A. Springer. 1987. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 51:813–819.

Mould, A. P., and M. J. Humphries. 1991. Identification of a novel recognition sequence for the integrin αβ1 in the COOH-terminal heparin-binding domain of fibronectin. EMBO (Eur. Mol. Biol. Organ.) J. 10:4089–4095.

Mould, A. P., A. Komoriya, K. M. Yamada, and M. J. Humphries. 1991. The CS5 peptide is a second site in the IIECS region of fibronectin recognized by the integrin αβ1. Inhibition of αβ1 function by RGD peptide homologues. J. Biol. Chem. 266:3579–3585.

Nejima, Y., M. J. Humphries, A. P. Mould, A. Komoriya, K. M. Yamada, S. F. Schlossman, and C. Morimoto. 1990. VLA-4 mediates CD3 dependent CD4+ T cell activation via the CS1 alternatively spliced domain of fibronectin. J. Exp. Med. 172:1185–1192.

Osborn, L., C. Hession, R. Tizani, C. Vassallo, S. Lubowski, G. Chi-Rosso, and R. R. Lobb. 1989. Direct expression of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 59:1203–1211.

Picket, L. J., R. A. Warnock, A. R. Burres, C. M. Doerschuk, E. L. Berg, and E. C. Butcher. 1991. The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell. 66:921–933.

Postigo, A. A., R. Palido, M. R. Campanero, A. Acevedo, A. Garcia-Pardo, A. L. Corbf, F. Sánchez-Madrid, and M. O. de Landázuri. 1991. Differential expression of VLA-4 integrin by resident and peripheral blood B lymphocytes. Acquistion of functionally active αβ1 fibronectin receptors upon B cell activation. Eur. J. Immunol. 21:2437–2445.

Postigo, A. A., R. García-Vicuña, F. Díaz-González, A. G. Arroyo, M. O. de Landázuri, G. Chi-Rosso, R. Lobb, A. Laffón, and F. Sánchez-Madrid. 1992. Increased binding of synovial T lymphocytes from Rheumatoid Arthritis to endothelial-leukocyte adhesion molecule-1 (ELAM-1) and vascular cell adhesion molecule-1 (VCAM-1). J. Clin. Invest. 89:1445–1452.

Robinson, M. K., D. Andrew, H. Rosen, D. Brown, S. Ortlapp, P. Stephens, and E. C. Butcher. 1992. Antibody against the Leu-CAM β-chain (CD11b) promotes both LFA-1 and CR3-dependent adhesion events. J. Immunol. 148:1080–1085.

Roldán, E., A. García-Pardo, and J. A. Brieva. 1992. VLA-4 fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion. J. Exp. Med. 175:1739–1747.

Rosen, G. D., J. R. Sanes, R. LaChance, J. M. Cunningham, J. Roman, and D. C. Dean. 1992. Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis. Cell. 69:1107–1119.

Rosenman, S. J., A. A. Ganji, T. F. Tedder, and W. M. Gallatin. 1993. Syncapping of human T lymphocyte adhesion/activation molecules and their redistribution during interaction with endothelial cells. J. Leukocyte Biol. 53:1–10.

Rothlein, R., M. L. Dustin, S. D. Marlin, and T. A. Springer. 1986. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J. Immunol. 137:1270–1274.

Sánchez-Madrid, F., J. Nagy, E. Robbins, P. Simon, and T. A. Springer. 1983. A human leukocyte differentiation antigen family with distinct α-subunits and a common β-subunit: the lymphocyte function-associated antigen (LFA-1), the CD11b complement receptor (OKM1-Mac-1), and the p150,95 molecule. J. Exp. Med. 158:1785–1803.

Sánchez-Madrid, F., M. O. de Landázuri, G. Morago, M. Cebrián, A. Acevedo, and C. Bernabéu. 1986. VLA-3: a novel polypeptide association within the VLA complex: cell distribution and biochemical characterization. Eur. J. Immunol. 16:1343–1349.

Sánchez-Mateos, P., A. G. Arroyo, M. A. Balboa, and F. Sánchez-Madrid. 1993. Post-receptor occupancy events in lymphocytes during β1 integrin-ligand interactions. Eur. J. Immunol. 23:2642–2648.

Shimizu, Y., G. A. van Seventer, K. J. Horgan, and S. Shaw. 1990. Regulated expression and binding of three VLA (β1) integrin receptors on T cells. Nature (Lond.). 345:250–253.

Smith, C. W., R. Rothlein, B. J. Hughes, M. M. Mariscalco, H. E. Rudluff, F. C. Schmalstieg, and D. C. Anderson. 1988. Recognition of an endothelial determinant for CD18-dependent human neutrophil adherence and transendothelial migration. J. Clin. Invest. 82:1746–1756.

Spits, H., H. Yssel, J. Leeuwenberg, and J. E. De Vries. 1985. Antigen-specific cytotoxic T cell and antigen-specific proliferation T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur. J. Immunol. 15:88–91.

Springer, T. A. 1990. Adhesion receptors of the immune system. Nature (Lond.). 346:425–434.

Staunton, D. E., M. L. Dustin, and T. A. Springer. 1989. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature (Lond.). 339:361–364.

Te Velde, A. A., J. P. G. Klamp, B. A. Yard, J. E. de Vries, and C. G. Figdor. 1988. Modulation of phenotypic and functional properties of human blood monocytes by IL-4. J. Immunol. 140:1548–1554.

Van Kooyk, Y., P. W. Weder, F. Hogervorst, A. J. Verhoeven, G. van Seventer, A. A. te Velde, J. Borst, G. D. Keizer, and C. G. Figdor. 1991. Activation of LFA-1 through a Ca2+-dependent epitope stimulates lymphocyte adhesion. J. Cell Biol. 112:345–354.

Van Seventer, G. A., W. Newman, Y. Shimizu, T. B. Nutman, Y. Tanaka, K. J. Horgan, T. V. Gopal, E. Ennis, D. O'Sullivan, H. Grey, and S. Shaw. 1991. Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J. Exp. Med. 174:901–913.

Vazeux, R., P. A. Hoffman, J. K. Tomita, E. S. Dickinson, R. L. Jasman, T. St. John, and W. M. Gallatin. 1992. Cloning and characterization of a new intercellular adhesion molecule ICAM-R. Nature (Lond.). 360:485–488.

Wayner, E. A., A. García-Pardo, M. J. Humphries, A. A. MacDonald, and W. G. Carter. 1989. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J. Cell Biol. 109:1321–1330.

Williams, D. A., M. Rios, C. Stephanos, and V. P. Patel. 1991. Fibronectin and CD4+ T cell activation via the CS 1 alternatively spliced domain of fibronec-